In addition to targeting immune inhibitory receptors such as PD-1, generating optimal anti-tumor response also requires T-cell receptor activation plus co-stimulation, such as by tumor necrosis factor receptor family members (TNFRSF), OX-40 (CD134), and 4-1BB (CD137) [5, 6]. This evidence concerns the gene TNFRSF4 and neoplasm.